Cipla Ltd. — Regulatory Filings 2021

Dec 28, 2021

==> picture [84 x 30] intentionally omitted <==

28[th] December 2021

(1) BSE Limited (2) National Stock Exchange of India Limited Listing Department, Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5[th] floor, Dalal Street, Plot no. C/1, G Block, Mumbai 400 001 Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Code: 500087 Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg

Sub: Corrigendum to the Press Release

Dear Sir / Madam,

In reference to the press release titled “Cipla receives Emergency Use Authorisation (EUA) to launch oral antiviral drug Cipmolnu® (Molnupiravir 200 mg) in India to treat mild to moderate COVID-19 at high risk of developing severe disease” issued on 28[th] December 2021, the Company would like to clarify that it has received EUA to launch Cipmolnu® (Molnupiravir 200 mg) in India for treatment of adult patients with COVID19, with SpO2>93% and who have high risk of disease progression including hospitalization or death.

This is for your information and records.

Kindly acknowledge the receipt.

Thanking you

Yours faithfully,

For Cipla Limited

RAJENDR Digitally signed by RAJENDRA A KUMAR KUMAR CHOPRA Date: 2021.12.28 CHOPRA 17:42:01 +05'30'

Rajendra Chopra Company Secretary

Prepared by: Mandar Kurghode

Cipla Ltd. Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India P +91 22 24826000 F +91 22 24826120 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Numbe r L24239MH1935PLC002380